4547 KISSEI PHARMACEUTICAL CO.,LTD. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4547

TSE Prime

KISSEI PHARMACEUTICAL CO.,LTD.

3,820

JPY

+265

(+7.45%)

Dec 25, 12:55 pm JST

24.32

USD

Dec 24, 10:55 pm EST

Result

PTS

outside of trading hours

3,819.5

Dec 25, 12:57 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2021	69,044	1,505	3,476	5,285	113.3	54	May 11, 2021	J-GAAP
Mar, 2022	65,381	-1,402	562	12,921	280.2	56	May 10, 2022	J-GAAP
Mar, 2023	67,493	-1,129	598	10,528	228.3	80	May 8, 2023	J-GAAP
Mar, 2024	75,579	4,017	6,142	11,160	246.6	82	May 7, 2024	J-GAAP
Mar, 2025 Guidance	86,500	5,000	6,000	11,700	273.3	90	Nov 5, 2024	J-GAAP
YoY	+14.4%	+24.5%	-2.3%	+4.8%	+10.8%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2020	May 8, 2019	61,400	1,000	2,200	2,700	52	J-GAAP
	Nov 6, 2019	62,000	1,500	2,700	2,900	52	J-GAAP
Results	May 12, 2020	63,234	1,857	2,429	2,817	52	J-GAAP
Mar, 2021	May 12, 2020	Available in future release
	Nov 5, 2020
	Apr 23, 2021
Results	May 11, 2021
Mar, 2022	May 11, 2021
	Nov 9, 2021
	Apr 22, 2022
Results	May 10, 2022
Mar, 2023	May 10, 2022
	Nov 8, 2022
	Apr 21, 2023
Results	May 8, 2023
Mar, 2024	May 8, 2023
	Nov 6, 2023
Results	May 7, 2024
Mar, 2025	May 7, 2024	83,000	4,200	5,400	11,300	90	J-GAAP
	Nov 5, 2024	86,500	5,000	6,000	11,700	90	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2000	57,029	+1.9	Available in future release
Mar, 2001	58,936	+3.3
Mar, 2002	59,929	+1.7
Mar, 2003	59,528	-0.7
Mar, 2004	58,225	-2.2
Mar, 2005	60,933	+4.7
Mar, 2006	64,007	+5.0
Mar, 2007	64,215	+0.3
Mar, 2008	61,480	-4.3
Mar, 2009	64,535	+5.0
Mar, 2010	62,178	-3.7
Mar, 2011	64,393	+3.6
Mar, 2012	64,618	+0.3
Mar, 2013	62,491	-3.3
Mar, 2014	70,399	+12.7
Mar, 2015	70,110	-0.4
Mar, 2016	71,294	+1.7
Mar, 2017	71,706	+0.6
Mar, 2018	74,009	+3.2
Mar, 2019	72,297	-2.3
Mar, 2020	63,234	-12.5
Mar, 2021	69,044	+9.2
Mar, 2022	65,381	-5.3
Mar, 2023	67,493	+3.2
Mar, 2024	75,579	+12.0
Mar, 2025 Guidance	86,500	+14.4	5,000	+24.5	6,000	-2.3	273.3	+10.8

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2023	67,493	-1,129	-1.7	5.33	4.58	0.29	228.3
Mar, 2024	75,579	4,017	5.31	5.39	4.63	0.31	246.6
Mar, 2025 Guidance	86,500	5,000	5.78	5.33	4.49	0.33	273.3

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	75,579	14,506	14,823	12,921	280.2
Fiscal Year	Mar, 2024	Mar, 1996	Mar, 1996	Mar, 2022	Mar, 2022

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2021	32,993	-1,672	-719	7,255	157.3	28	May 10, 2022	J-GAAP
Oct - Mar, 2022	34,629	-504	290	7,202	156.2	40	May 8, 2023	J-GAAP
Oct - Mar, 2023	38,601	2,002	2,677	5,482	121.1	41	May 7, 2024	J-GAAP
Oct - Mar, 2024 Guidance	44,034	3,219	3,763	6,451	150.7	45	Nov 5, 2024	J-GAAP
YoY	+14.1%	+60.8%	+40.6%	+17.7%	+24.4%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2022	-1,402	12,309	1,533	10,776	-2,756	53,004	22.26	J-GAAP
Mar, 2023	-1,129	-678	-6,679	6,001	-3,420	48,884	22.10	J-GAAP
Mar, 2024	4,017	7,013	-1,677	8,690	-10,006	45,887	17.59	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2022	32,864	-625	308	3,326	72.1	51.5	Nov 8, 2022	J-GAAP
Apr - Sep, 2023	36,978	2,015	3,465	5,678	123.7	56.4	Nov 6, 2023	J-GAAP
Apr - Sep, 2024	42,466	1,781	2,237	5,249	118.8	37.3	Nov 5, 2024	J-GAAP
YoY	+14.8%	-11.6%	-35.4%	-7.6%	-4.0%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2022	18,771	1,117	1,805	3,341	72.5	6.0	Jan 31, 2023	J-GAAP
Jan - Mar, 2023	15,858	-1,621	-1,515	3,861	83.7	-10.2	May 8, 2023	J-GAAP
Apr - Jun, 2023	19,313	1,633	2,712	3,265	71.0	8.5	Jul 31, 2023	J-GAAP
Jul - Sep, 2023	17,665	382	753	2,413	52.6	2.2	Nov 6, 2023	J-GAAP
Oct - Dec, 2023	20,881	2,149	2,635	2,659	58.3	10.3	Jan 30, 2024	J-GAAP
Jan - Mar, 2024	17,720	-147	42	2,823	62.4	-0.8	May 7, 2024	J-GAAP
Apr - Jun, 2024	21,164	2,158	2,876	4,106	92.9	10.2	Jul 30, 2024	J-GAAP
Jul - Sep, 2024	21,302	-377	-639	1,143	25.9	-1.8	Nov 5, 2024	J-GAAP
YoY	+20.6%	－	－	-52.6%	-50.8%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2019	17,004	-13.2	Available in future release
Jan - Mar, 2020	14,682	-13.8
Apr - Jun, 2020	16,061	-0.2
Jul - Sep, 2020	16,223	+5.0
Oct - Dec, 2020	19,911	+17.1
Jan - Mar, 2021	16,849	+14.8
Apr - Jun, 2021	16,635	+3.6
Jul - Sep, 2021	15,753	-2.9
Oct - Dec, 2021	17,697	-11.1
Jan - Mar, 2022	15,296	-9.2
Apr - Jun, 2022	16,285	-2.1
Jul - Sep, 2022	16,579	+5.2
Oct - Dec, 2022	18,771	+6.1
Jan - Mar, 2023	15,858	+3.7
Apr - Jun, 2023	19,313	+18.6
Jul - Sep, 2023	17,665	+6.6
Oct - Dec, 2023	20,881	+11.2
Jan - Mar, 2024	17,720	+11.7
Apr - Jun, 2024	21,164	+9.6
Jul - Sep, 2024	21,302	+20.6	-377	－	-639	－	25.9	-50.8

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	21,434	6,819	7,288	6,102	132.3
Fiscal Year	Dec, 2013	Dec, 2013	Dec, 2013	Mar, 2022	Mar, 2022

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2022	4,366.96	84.6	238,087	201,385	118,183	0.01	May 10, 2022	J-GAAP
Mar, 2023	4,204.64	87.7	221,200	193,899	125,576	0.01	May 8, 2023	J-GAAP
Mar, 2024	4,977.41	84.3	260,929	220,028	127,310	0.01	May 7, 2024	J-GAAP
Apr - Sep, 2024	4,969.04	84.4	260,339	219,657	130,747	0.01	Nov 5, 2024	J-GAAP

KISSEI PHARMACEUTICAL CO.,LTD.(4547) Financial Results